



Case #PC027829A

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE APPLICATION OF
Jerry R. Colca

GROUP ART UNIT: 1635

SERIAL NO: 10/728,399

EXAMINER: Amy Hudson Bowman

FILED: December 5, 2003

DATE: February 9, 2006

TITLE: Antisense Modulation of mitoNEET Expression

SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT
UNDER 37 CFR 1.97-1.98

Commissioner for Patents
Alexandria, VA 22313

Sir:

This Supplemental Information Disclosure Statement is filed pursuant to 37 CFR 1.97-1.98 and MPEP §609. The present Information Disclosure Statement supplements the Information Disclosure Statement previously filed on March 3, 2005. Any fee required by 37 CFR 1.97-1.98 should be charged to Deposit Account No. 19-1025.

This newly cited document is as pertinent as the documents previously cited in this prosecution.

Respectfully submitted,

S. Christopher Bauer
Agent for Applicant
Registration No. 42,305
Tel: 314-274-6257

Pharmacia Corporation
Of Pfizer Inc
Corporate Patent Department
P.O. Box 1027
Chesterfield, MO 63006



Sheet 1 of 2

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE, PATENT AND TRADEMARK OFFICE SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)	ATTY. DOCKET NO: PC027829A	APPLICATION NO.: 10/728,399
	INVENTOR: Jerry R. Colca	
	Filed: 12/5/03	Group: 1635

U.S. PATENT DOCUMENTS

Examiner Initial	Document Number	Date	Name	Class	Subclass	Filing Date If Appropriate
	US 5,801,154A	9/1/98	Baracchini, et al.			
	US5,998,148A	12/7/99	Bennett, et al.			

FOREIGN PATENT DOCUMENTS

Examiner Initial							Translation	
	Document Number	Date	Country	Class	Subclass		Yes	No
	B1 WO 03/031571 A2	4/17/03	WO	C12N				

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	

FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE, PATENT AND TRADEMARK OFFICE SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use several sheets if necessary)	ATTY. DOCKET NO: PC027829A	APPLICATION NO.: 10/728,399
	INVENTOR: Jerry R. Colca	
	Filed: 12/5/03	Group: 1635

OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

Examiner Initial		
	C1	Collins, F. S., <i>Generation and Initial Analysis of More than 15,000 Full-Length Human and Mouse CDNA Sequences</i> , December 24, 2002, Vol. 99, No. 26, pgs. 16899-16903
	C2	Taylor, M. F., et al., <i>Antisense Oligonucleotides: A Systematic High-Throughput Approach to Target Validation and Gene Function Determination</i> , DDT. , December 1999, Vol. 4, No. 12, pgs. 562-567
	C3	Jen, K, et al., <i>Suppression of Gene Expression by Targeted Disruption of Messenger RNA: Available Options and Current Strategies</i> . Stem Cells, 2000, Vol. 18, pgs. 307-319
	C4	Branch, A.D., <i>A Good Antisense Molecule is Hard to Find</i> , TIBS, February 1998, pgs. 45-50
	C5	Green, D. W., et al., <i>Antisense Oligonucleotides: An Evolving Technology for the Modulation of Gene Expression in Human Disease</i> , J. Am. Coll. Surg., Vol. 191, No. 1, July 2000, pgs. 93-105

EXAMINER	DATE CONSIDERED
EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	